Biotechnology firm Oncoheroes Biosciences, a CataloniaBio & HealthTech member with offices in Boston and Barcelona, has signed two agreements to receive philanthropic investments from the Catalytic Impact Foundation and the Gregory Foundation for Cancer Research in the United States.

Both of these foundations value Oncoheroes’ innovative approach to the urgent need for treatment designed specifically for children with cancer, the social impact of their activity, and the fact that it is an early-stage startup. The Gregory Foundation had invested in the company previously.The sum invested through these agreements has not been disclosed.

“We’re happy to see that more non-profit organisations are recognising the role of an industrial partner like Oncoheroes in developing new paediatric cancer drugs and are committing to venture philanthropy,” notes Ricardo Garcia, co-founder and CEO of Oncoheroes.

Moreover, Oncoheroes announced they have entered into a partnership with Shepherd Therapeutics to collaborate in the discovery, development and commercialization of innovative drug products for rare oncology indications.

You may also be interested in:

• Oncoheroes gets orphan drug designation in United States for volasertib
• Oncoheroes will receive $1.1 million of Dreamers Ventures
• Oncoheroes and Boehringer Ingelheim sign a licensing agreement for volasertib